| dbo:abstract |
Trilaciclib ist ein Arzneistoff aus der Wirkstoffgruppe der CDK-Inhibitoren. Als erster Vertreter der Klasse der Myeloprotektoren (first in class) wurde Trilaciclib 2021 in den USA als Cosela zugelassen, um die Häufigkeit von Chemotherapie-induzierter Knochenmarksunterdrückung bei kleinzelligem Lungenkrebs zu vermindern. (de) Trilaciclib, sold under the brand name Cosela, is a medication used to reduce the frequency of chemotherapy-induced bone marrow suppression. The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia). Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin-dependent kinase 4/6, a type of enzyme. Trilaciclib is the first therapy in its class and was approved for medical use in the United States in February 2021. Chemotherapy drugs are designed to kill cancer cells but can damage normal tissues as well. The bone marrow is particularly susceptible to chemotherapy damage. The bone marrow makes red blood cells, white blood cells, and platelets (small fragments in the blood) that transport oxygen, fight infection, and stop bleeding. When damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection, and bleeding, among other problems. Trilaciclib may help protect the normal bone marrow cells from the harmful effects of chemotherapy. (en) |
| dbo:alternativeName |
Cosela (en) |
| dbo:casNumber |
1374743-00-6 |
| dbo:chEMBL |
3894860 |
| dbo:class |
dbr:CDK_inhibitor |
| dbo:drugbank |
DB15442 |
| dbo:fdaUniiCode |
U6072DO9XG |
| dbo:kegg |
D11130 |
| dbo:pubchem |
68029831 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Trilaciclib.svg?width=300 |
| dbo:wikiPageExternalLink |
https://www.fda.gov/ https://druginfo.nlm.nih.gov/drugportal/name/trilaciclib |
| dbo:wikiPageID |
53100045 (xsd:integer) |
| dbo:wikiPageLength |
9424 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1079878846 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Priority_review dbr:Cyclin-dependent_kinase dbr:Indication_(medicine) dbc:Guanidines dbc:Piperazines dbc:Spiro_compounds dbc:Chemotherapeutic_adjuvants dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbc:Pyridines dbc:Amides dbc:Breakthrough_therapy dbc:Protein_kinase_inhibitors dbr:CDK_inhibitor dbr:Medication dbr:Intravenous |
| dbp:atcPrefix |
V03 (en) |
| dbp:atcSuffix |
AF12 (en) |
| dbp:c |
24 (xsd:integer) |
| dbp:casNumber |
1374743 (xsd:integer) |
| dbp:chembl |
3894860 (xsd:integer) |
| dbp:chemspiderid |
58825997 (xsd:integer) |
| dbp:class |
dbr:CDK_inhibitor |
| dbp:dailymedid |
Trilaciclib (en) |
| dbp:drugbank |
DB15442 (en) |
| dbp:h |
30 (xsd:integer) |
| dbp:iupacName |
4 (xsd:integer) |
| dbp:kegg |
D11130 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:n |
8 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
68029831 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:smiles |
CN1CCNC1=CN=CC=C1 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
PDGKHKMBHVFCMG-UHFFFAOYSA-N (en) |
| dbp:tradename |
Cosela (en) |
| dbp:unii |
U6072DO9XG (en) |
| dbp:wikiPageUsesTemplate |
dbt:HHS_content dbt:Cite_web dbt:IPAc-en dbt:Infobox_drug dbt:Pharma-stub dbt:Portal_bar dbt:Reflist dbt:Respell dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Targeted_cancer_therapeutic_agents |
| dct:subject |
dbc:Guanidines dbc:Piperazines dbc:Spiro_compounds dbc:Chemotherapeutic_adjuvants dbc:Pyridines dbc:Amides dbc:Breakthrough_therapy dbc:Protein_kinase_inhibitors |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Trilaciclib ist ein Arzneistoff aus der Wirkstoffgruppe der CDK-Inhibitoren. Als erster Vertreter der Klasse der Myeloprotektoren (first in class) wurde Trilaciclib 2021 in den USA als Cosela zugelassen, um die Häufigkeit von Chemotherapie-induzierter Knochenmarksunterdrückung bei kleinzelligem Lungenkrebs zu vermindern. (de) Trilaciclib, sold under the brand name Cosela, is a medication used to reduce the frequency of chemotherapy-induced bone marrow suppression. The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia). (en) |
| rdfs:label |
Trilaciclib (de) Trilaciclib (en) |
| owl:sameAs |
wikidata:Trilaciclib dbpedia-de:Trilaciclib https://global.dbpedia.org/id/FpbH9 |
| prov:wasDerivedFrom |
wikipedia-en:Trilaciclib?oldid=1079878846&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Trilaciclib.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Trilaciclib |
| is dbo:wikiPageRedirects of |
dbr:Cosela dbr:Trilaciclib_dihydrochloride |
| is dbo:wikiPageWikiLink of |
dbr:2021_in_the_United_States dbr:Boehringer_Ingelheim dbr:G1_Therapeutics dbr:Small-cell_carcinoma dbr:Cosela dbr:ATC_code_V03 dbr:Chemotherapy dbr:Bone_marrow_suppression dbr:CDK_inhibitor dbr:Trilaciclib_dihydrochloride |
| is foaf:primaryTopic of |
wikipedia-en:Trilaciclib |
